Skip to content 
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida. more
| Time Frame | ASBP | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 1.42% | 1.51% | -1.5% |
| 1-Month Return | -28.86% | 1.46% | 0.6% |
| 3-Month Return | -60.84% | 3.94% | 2.43% |
| 6-Month Return | -93.94% | 16.03% | 6.01% |
| 1-Year Return | -99.42% | 9.1% | 11.48% |
| 3-Year Return | -99.66% | 19.46% | 67.52% |
| 5-Year Return | -99.64% | 35.29% | 73.75% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | |||
|---|---|---|---|---|---|---|
| Total Revenue | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |
| Cost of Revenue | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |
| Gross Profit | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |
| Gross Margin | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |
| Operating Expenses | 25.48K | 976.35K | 1.34M | 3.09M | [{"date":"2021-12-31","value":0.82,"profit":true},{"date":"2022-12-31","value":31.61,"profit":true},{"date":"2023-12-31","value":43.38,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] | |
| Operating Income | (25.48K) | (976.35K) | (1.34M) | (3.09M) | [{"date":"2021-12-31","value":-2548000,"profit":false},{"date":"2022-12-31","value":-97634500,"profit":false},{"date":"2023-12-31","value":-134000000,"profit":false},{"date":"2024-12-31","value":-308867100,"profit":false}] | |
| Total Non-Operating Income/Expense | - | 4.32M | 11.61M | (9.79M) | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":37.19,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-84.35,"profit":false}] | |
| Pre-Tax Income | (25.48K) | 3.34M | 4.46M | (12.54M) | [{"date":"2021-12-31","value":-0.57,"profit":false},{"date":"2022-12-31","value":74.82,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-280.85,"profit":false}] | |
| Income Taxes | - | 626.00 | 481.00 | 1.01K | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":61.8,"profit":true},{"date":"2023-12-31","value":47.48,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] | |
| Income After Taxes | - | 3.34M | 4.46M | (12.54M) | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":74.81,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-280.9,"profit":false}] | |
| Income From Continuous Operations | - | (597.12K) | (359.07K) | (12.54M) | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-59711700,"profit":false},{"date":"2023-12-31","value":-35907100,"profit":false},{"date":"2024-12-31","value":-1253747200,"profit":false}] | |
| Income From Discontinued Operations | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |
| Net Income | (25.48K) | 3.34M | 4.46M | (12.54M) | [{"date":"2021-12-31","value":-0.57,"profit":false},{"date":"2022-12-31","value":74.82,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-280.85,"profit":false}] | |
| EPS (Diluted) | - | 0.09 | 1.38 | (17.74) | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":6.75,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-1282.55,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
| ASBP | |
|---|---|
| Cash Ratio | 0.14 |
| Current Ratio | 0.17 |
| Quick Ratio | 0.17 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| ASBP | |
|---|---|
| ROA (LTM) | -195.11% |
| ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| ASBP | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 5.77 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -4.77 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| ASBP | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 3528.95 |
| P/B | 0.00 |
| Price/FCF | NM |
| EV/R | 6968.66 |
| EV/Ebitda | NM |
Aspire BioPharma, Inc. (ASBP) share price today is $1.59
Yes, Indians can buy shares of Aspire BioPharma, Inc. (ASBP) on Vested. To buy
Yes, you can purchase fractional shares of Aspire BioPharma, Inc. (ASBP) via the Vested app. You can start investing in Aspire BioPharma, Inc. (ASBP) with a minimum investment of $1.
You can invest in shares of Aspire BioPharma, Inc. (ASBP) via Vested in three simple steps:
The 52-week high price of Aspire BioPharma, Inc. (ASBP) is $394.4. The 52-week low price of Aspire BioPharma, Inc. (ASBP) is $1.2.
The price-to-earnings (P/E) ratio of Aspire BioPharma, Inc. (ASBP) is
The price-to-book (P/B) ratio of Aspire BioPharma, Inc. (ASBP) is 0.00
The dividend yield of Aspire BioPharma, Inc. (ASBP) is 0.00%
The market capitalization of Aspire BioPharma, Inc. (ASBP) is $6.85M
The stock symbol (or ticker) of Aspire BioPharma, Inc. is ASBP
Consider the share price of Aspire BioPharma, Inc. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Aspire BioPharma, Inc. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Aspire BioPharma, Inc. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Aspire BioPharma, Inc. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Aspire BioPharma, Inc. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Aspire BioPharma, Inc. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
